Literature DB >> 18401018

Total cholesterol and the risk of Parkinson disease.

G Hu1, R Antikainen, P Jousilahti, M Kivipelto, J Tuomilehto.   

Abstract

OBJECTIVE: To examine the association between serum total cholesterol at baseline and the risk of Parkinson disease (PD).
METHODS: Study cohorts included 24,773 Finnish men and 26,153 women aged 25 to 74 years without a history of PD and stroke at baseline. Hazard ratios (HRs) of incident PD were estimated for different levels of total cholesterol.
RESULTS: During a mean follow-up period of 18.1 years, 321 men and 304 women developed incident PD. After adjustment for confounding factors (age, study years, body mass index, systolic blood pressure, education, leisure-time physical activity, smoking, alcohol consumption, coffee and tea consumption, and history of diabetes), the HRs of PD at different levels of total cholesterol (<5, 5-5.9, 6-6.9, and >or=7 mmol/L) were 1.00, 1.33, 1.53, and 1.84 (p for trend = 0.035) in men; 1.00, 1.55, 1.57, and 1.86 (p for trend = 0.113) in women; and 1.00, 1.42, 1.56, and 1.86 (p for trend = 0.002) in men and women combined (adjusted also for sex). In both sexes combined, the increased risk of PD associated with increasing levels of serum total cholesterol was present both in subjects aged 25-44 years and in subjects aged 45-54 years at baseline, and in never smokers and smokers; however, no association was found among subjects aged 55 years or older at baseline.
CONCLUSION: This large prospective study suggests that high total cholesterol at baseline is associated with an increased risk of Parkinson disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18401018     DOI: 10.1212/01.wnl.0000312511.62699.a8

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  64 in total

1.  The oxysterol 27-hydroxycholesterol regulates α-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors--relevance to Parkinson's disease.

Authors:  Gurdeep Marwarha; Turk Rhen; Trevor Schommer; Othman Ghribi
Journal:  J Neurochem       Date:  2011-10-24       Impact factor: 5.372

2.  Associations between cerebrovascular risk factors and parkinson disease.

Authors:  Benjamin R Kummer; Iván Diaz; Xian Wu; Ashley E Aaroe; Monica L Chen; Costantino Iadecola; Hooman Kamel; Babak B Navi
Journal:  Ann Neurol       Date:  2019-08-29       Impact factor: 10.422

3.  Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.

Authors:  Xuemei Huang; Alvaro Alonso; Xuguang Guo; David M Umbach; Maya L Lichtenstein; Christie M Ballantyne; Richard B Mailman; Thomas H Mosley; Honglei Chen
Journal:  Mov Disord       Date:  2015-01-14       Impact factor: 10.338

4.  Statin use and Parkinson's disease in Denmark.

Authors:  Beate Ritz; Angelika D Manthripragada; Lei Qian; Eva Schernhammer; Lene Wermuth; Jorgen Olsen; Soren Friis
Journal:  Mov Disord       Date:  2010-07-15       Impact factor: 10.338

Review 5.  LXR agonists: new potential therapeutic drug for neurodegenerative diseases.

Authors:  Pei Xu; Dabing Li; Xiaotong Tang; Xiaohang Bao; Jing Huang; Yongping Tang; Yang Yang; Haiwei Xu; Xiaotang Fan
Journal:  Mol Neurobiol       Date:  2013-04-27       Impact factor: 5.590

6.  APOE and LRPAP1 gene polymorphism and risk of Parkinson's disease.

Authors:  Neeraj Kumar Singh; Basu Dev Banerjee; Kiran Bala; Aldrin Anthony Dung Dung; Neelam Chhillar
Journal:  Neurol Sci       Date:  2014-02-07       Impact factor: 3.307

Review 7.  Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease-Parkinson's disease overlap?

Authors:  Gurdeep Marwarha; Othman Ghribi
Journal:  Exp Gerontol       Date:  2014-09-28       Impact factor: 4.032

8.  Blood profile holds clues to role of infection in a premonitory state for idiopathic parkinsonism and of gastrointestinal infection in established disease.

Authors:  André Charlett; R John Dobbs; Sylvia M Dobbs; Clive Weller; Mohammad A A Ibrahim; Tracy Dew; Roy Sherwood; Norman L Oxlade; J Malcolm Plant; James Bowthorpe; Andrew J Lawson; Alan Curry; Dale W Peterson; Ingvar T Bjarnason
Journal:  Gut Pathog       Date:  2009-11-26       Impact factor: 4.181

9.  Reply: Plasma cholesterol and Parkinson's disease: Is the puzzle only apparent?

Authors:  Xuemei Huang; Honglei Chen; Helen Petrovitch; Richard Mailman; Webster Ross
Journal:  Mov Disord       Date:  2010-01-15       Impact factor: 10.338

10.  Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies.

Authors:  Andrew O Koob; Kiren Ubhi; Johan F Paulsson; Jeffery Kelly; Edward Rockenstein; Michael Mante; Anthony Adame; Eliezer Masliah
Journal:  Exp Neurol       Date:  2009-11-26       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.